Systemic treatment options for advanced BRAF V600‐mutant melanoma include BRAF/MEK inhibitors (BRAF/MEKi), anti‐PD‐1 monotherapy (Anti‐PD‐1), combination of anti‐PD‐1 antibody plus anti‐CTLA‐4 antibody (PD‐1/CTLA‐4), and recently added combination of relatlimab, anti‐LAG‐3 antibody, and nivolumab (relatlimab–nivolumab). This evidence concerns the gene MAP2K7 and melanoma.